Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma.

CONCLUSIONS: Our pre-clinical efficacy studies support the further optimization of the 64B chemical scaffold towards a clinical candidate for the treatment of UM.
PMID: 30563937 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 18, 2018 Category: Cancer & Oncology Authors: Van Meir EG, Dong L, You S, Zhang Q, Osuka S, Devi NS, Kaluz S, Holmes JN, Yang H, Chen G, Wang B, Grossniklaus HE Tags: Clin Cancer Res Source Type: research